• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Scott R. Plotkin, MD, PhD


  • Terry AR, Barker FG, Leffert L, Bateman BT, Souter I, Plotkin SR.Neurofibromatosis type 1 and pregnancy complications: a┬ápopulation-based study.Am J Obstet Gynecol. 2013 Mar 25.
  • Smith MJ, Esparza S, Merker VL, Muzikansky A, Bredella MA, Harris GJ, Kassarjian A, Cai W, Walker JA, Mautner VF, Plotkin SR.Plasma S100╬▓ is not a useful biomarker for tumor burden in neurofibromatosis.Clin Biochem. 2013 May;46(7-8):698-700.
  • Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY.Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.Neuro Oncology. 2013 Apr 3.
  • Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, Barker FG, Stemmer-Rachamimov A, Plotkin SR.Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients.PLoS ONE. 2013;8(3):e59941.
  • Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M.Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.Am J Med Genet A. 2013 Mar;161(3):405-16.
  • Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR.Clinical features of schwannomatosis: a retrospective analysis of 87 patients.Oncologist. 2012;17(10):1317-22.
  • Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z.Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis Type 1.J Neurosurg. 2012 Oct 26.
  • Wirth LJ, Plotkin SR, Emerick KS, Cunnane ME, Faquin WC.Case records of the Massachusetts General Hospital. Case 29-2012. A 49-year-old man with pain and cranial-nerve palsies after treatment of oral cancer.N Engl J Med. 2012 Sep 20;367(12):1136-47.
  • Smith MJ, Walker JA, Shen Y, Stemmer-Rachamimov A, Gusella JF, Plotkin SR.Expression of SMARCB1 (INI1) mutations in familial schwannomatosis.Hum Mol Genet. 2012 Sep 12.
  • Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, Plotkin SR.Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome.Genet Med. 2012 Aug 9.
  • Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG.Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.Otol. Neurotol. 2012 Aug;33(6):1046-52.
  • Terry AR, Barker FG, Leffert L, Bateman BT, Souter I, Plotkin SR.Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study.Neuro Oncology. 2012 Jun;14(6):768-76.
  • Plotkin SR, O'Donnell CC, Curry WT, Bove CM, Maccollin M, Nunes FP.Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients.J Neurosurg Spine. 2011 Apr;14(4):543-7.
  • Jeyaretna DS, Curry WT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR.Exacerbation of cerebral radiation necrosis by bevacizumab.J Clin Oncol. 2011 Mar 1;29(7):e159-62.
  • di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK.Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.Cancer Res. 2011 Jan 1;71(1):19-28.
  • Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT.Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.J. Neurooncol. 2010 Sep 7.
  • Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG.Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.Otol. Neurotol. 2010 Sep;31(7):1135-43.
  • Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK.Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.J Clin Oncol. 2010 Jun 10;28(17):2817-23.
  • Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E.Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.Cancer Res. 2010 May 1;70(9):3483-93.
  • El-Jawahri A, Podgurski LM, Eichler AF, Plotkin SR, Temel JS, Mitchell SL, Chang Y, Barry MJ, Volandes AE.Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial.J Clin Oncol. 2010 Jan 10;28(2):305-10.
  • Lu-Emerson C, Plotkin SR.The neurofibromatoses. Part 2: NF2 and schwannomatosis.Reviews In Neurological Diseases. 2009;6(3):E81-6. Review.
  • Shen Y, Nunes F, Stemmer-Rachamimov A, James M, Mohapatra G, Plotkin S, Betensky RA, Engler DA, Roy J, Ramesh V, Gusella JF.Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.BMC Med Genomics. 2009;2:42.
  • Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E.Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.N Engl J Med. 2009 Jul 23;361(4):358-67.
  • James MF,Han S,Polizzano C,Plotkin SR,Manning BD,Stemmer-Rachamimov AO,Gusella JF,Ramesh V.NF2/Merlin is a Novel Negative Regulator of mTOR Complex 1 and Activation of mTORC1 is Associated with Meningioma and Schwannoma Growth.Mol Cell Biol. 2009 Aug;29(15):4250-61.
  • Lu-Emerson C, Plotkin SR.The Neurofibromatoses. Part 1: NF1.Reviews In Neurological Diseases. 2009;6(2):E47-53. Review.
  • Plotkin SR,Halpin C,Blakeley JO,Slattery WH 3rd,Welling DB,Chang SM,Loeffler JS,Harris GJ,Sorensen AG,McKenna MJ,Barker FG 2nd.Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.J Neurooncol. 2009 May;93(1):61-77. Review.
  • Cai W,Kassarjian A,Bredella MA,Harris GJ,Yoshida H,Mautner VF,Wenzel R,Plotkin SR.Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.Radiology. 2009 Mar;250(3):665-73.
  • McQueen M,MacCollin M,Gusella J,Plotkin SR.Patient and physician attitudes regarding clinical trials in neurofibromatosis 1.J Neurosci Nurs. 2008 Dec;40(6):341-5.
  • Harris GJ,Plotkin SR,Maccollin M,Bhat S,Urban T,Lev MH,Slattery WH.Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II.Neurosurgery. 2008 Jun;62(6):1314-9; discussion 1319-20.
  • Eichler AF,Plotkin SR.Brain metastases.Curr Treat Options Neurol. 2008 Jul;10(4):308-14.
  • Plotkin SR,Singh MA,O'Donnell CC,Harris GJ,McClatchey AI,Halpin C.Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.Nat Clin Pract Oncol. 2008 Aug;5(8):487-91.
  • Wendell LC, Freeman SH, Plotkin SR, Sims JR.Clinical reasoning: a case of multiple intracerebral hemorrhages.Neurology. 2007 Dec 4;69(23):E30-4.
  • Farrell CJ, Plotkin SR.Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes.Neurol Clin. 2007 Nov;25(4):925-46, viii. Review.
  • James MF, Lelke JM, Maccollin M, Plotkin SR, Stemmer-Rachamimov AO, Ramesh V, Gusella JF.Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.Neurobiol Dis. 2008 Feb;29(2):278-92.
  • Bredella MA, Torriani M, Hornicek F, Ouellette HA, Plamer WE, Williams Z, Fischman AJ, Plotkin SR.Value of PET in the assessment of patients with neurofibromatosis type 1.AJR Am J Roentgenol. 2007 Oct;189(4):928-35.
  • Alcalay RN, Shulman JM, Plotkin SR.Ramsay Hunt syndrome in a patient with metastatic lung cancer to brain.J Neurooncol. 2008 Jan;86(1):55-6.
  • Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK.AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell. 2007 Jan;11(1):83-95.